morning all,
I will reply to 18041970 on this thread because it is more relevant than in a charting thread.
Re. the news ann. - this is at bare minimum confirmation that the company thinks that it is worth running with for another year - it could also mean that they are excited about it --------- only time will tell.
"What MedAdvisor appears to do quite well, is simply medication management."
Actually - it does it more than quite well from what I see - it does it very well.
"Competition, especially in the "Consumer App" space is always something I am wary of with these...."
Competition in the app. space is a constant --------- but, apps. are no different to any other business - an app. is really only the front end ------------ 'everything' behind it has to work and work well and integrate well for an app. or a business to perform well ----------- which, makes the 'app. competition' thing - fairly minor in reality.
That the app. needs to be good - yes, is crucial - but, a perfect app. is not worth a cent - if pharmacies don't get behind it or people don't use it.
It is pretty clear that this app. has that happening - and, yes, there is 'some' resistance in some quarters - but, there always are resistant quarters in technological change. I worked for a while in a Govt' department where the 'boss' resisted going to email from snail mail ------------- can you believe such a dinosaur act? -- Of course - eventually - and rapidly - the dinosaur was swept away in the rush of the tide of progress.
So - if this thing continues - most will change to it --------- bar perhaps the very old - who aren't into technology.
The big possible resistors in this are the doctors etc. -- they are dinosaurs - still, many records on paper - still some are handwriting - and, still many 2 fingered typists among them.
But, - the tide will sweep them away very very rapidly as well - it won't be MDR that will do it by itself --- AI is coming like a train - robot surgery is here - and digital records are here - and, none will survive if they don't convert.
The only questions for MDR are -- is the timing right? and can the company get the revenue they want from what areas they want - and, what other revenue areas will open up?
One thing in this world that works is money. It may well be the root of all evil - but, it is in fact the biggest driver of all (broadly) - if there is enough money to be made or enough money to be saved - AND it can be demonstrated - with little outlay or risk - then people will go for it ------------ even the medical profession.
Medication is a really really big deal in life ----------------- inappropriate medication is one of the biggest killers and injurers in our society - it is also one of the biggest costs - it is also one of the biggest areas of waste.
ANY company that can come in and hit this space with a money saving and/or making idea that runs - WILL do well - very well - it's that simple.
"Big risks, still not going to be profitable for a while yet (although the actual, existing revenue is a nice change from many others) so its far from a sure thing. I'm in for a punt, grabbed a few more today.. if this does a RAP, I don't want to miss it but not under any illusions that its a sure-thing."
Agree with the above ----------- there are just not enough runs on the board yet - and, in my case, not enough known about the team and team dynamic yet to make a high conviction buy - but, at the stage it is at -- IMO - it's worth a reasonable punt - and, if it comes off - it will pay handsomely. If it doesn't - then, I think it will be a low risk - or at least low loss punt/investment.
We shall see.
have a great day all.
- Forums
- ASX - By Stock
- MDR
- Ann: GlaxoSmithKline Extends Service Agreement with MedAdvisor-MDR.AX
MDR
medadvisor limited
Add to My Watchlist
3.33%
!
5.8¢

Ann: GlaxoSmithKline Extends Service Agreement with MedAdvisor-MDR.AX, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.8¢ |
Change
-0.002(3.33%) |
Mkt cap ! $38.14M |
Open | High | Low | Value | Volume |
6.0¢ | 6.3¢ | 5.7¢ | $71.93K | 1.203M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 119489 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 103882 | 0.059 |
3 | 253543 | 0.058 |
4 | 114117 | 0.057 |
2 | 16285 | 0.056 |
2 | 84486 | 0.055 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 30000 | 1 |
0.058 | 104544 | 1 |
0.059 | 200000 | 1 |
0.061 | 263179 | 1 |
0.063 | 90517 | 1 |
Last trade - 15.59pm 15/07/2025 (20 minute delay) ? |
Featured News
MDR (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online